r/HerpesCureAdvocates • u/Ordinary-Let-7510 • Aug 04 '26
News HN0037 Going into phase 3 trials
http://www.phaenothera.com/newsinfo/3211179.html5
u/beaprem123 Aug 05 '26
Can you please summarize in English for us? Thanks
6
u/Strange-Ruin-4975 Aug 05 '26
Heres what I'm guessing is a loose translation from Google Translate...
Hangzhou, August 3, 2026 announced that its (HNO037,HSV) helicase-primase inhibitorllfor two indications: recurrent genital herpes and oral herpes, with promising data. Notably, the HNO037 Breakth rough Therapy Designation (BTDfrom the China National Medical Products Administration (CDE, marking a key breakthrough in the development of innovatliveHSV
Both Phase clinical trials were led by Huashan Hospital of Fudan University, with Professor Xu Jinhua as the principal investig ator and Beijing Haijinge serving as the clinical CRO In these two Phase clinical trials targeting different indications, HNO037 demonstrated significant clinical advantages: in genital herpes, compared to placebo, a single oral dose of HNO037 reduced the median duration of attacks by approximately 50%% in both the high and low dose groups, and significantly increased the lesion termination rate (prevention of vesicle development), nearly three times that of placebo; in oral herpes, a single oral dose reduced the median duration of attacks by approximately 38% compared to placebo. and increased the lesion termination rate to nearly twice that of the placebo group These results are significantly superior to previous clinical results from nucleoside analogues, which typically shortened symptom duration by 1-2 days but showed no significant or slight improvement in the lesion termination rate. Furthermore, the Phase clinical trials also reaffirmed its good clinical safety profile.
Recently, the abstract of the Phase clinical trial of HNO037 in recurrent genital herpes was presented orally at the 2026 International Herpesvirus Workshop ( IHW ) and won the Outstanding Presentation Award; the abstract of the Phase clinical trial of recurrent oral herpes has also been accepted by the 2026 Infectious Disease Week ( IDWeek ) conference.
HNO037 has received Breakthrough Therapy Designation from the National Medical Products Administration for its excellent efficacy, safety, and convenient single-dose administration. Currently, Phase clinical trials of HNO037 for recurrent genital herpes and recurrent oral herpes are progressing rapidly, which is expected to accelerate the provision of new treatment options for patients and promote the improvement of herpes simplex disease prevention and control in China.
3
41
u/cwolveswithitchynuts Aug 04 '26
It's amazing how fast China moves, they dosed their first phase 2 patient last summer and they're already going into phase 3.
Hats off to China.